Pancreatic Cancer Research

ResearcherChampalimaud FoundationActive in the last 2 years

Christoph Springfeld

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0003-3843-101X; OpenAlex author ID A5016751143. Sources: OpenAlex.

Their work

Papers
52 (first author 6, last author 6)
Trials
0
Grants
0
Labs led
1
Collaborators
147
Papers, trials and grants by year

2013: 2 papers · 2014: 1 paper · 2015: 3 papers · 2016: 1 paper · 2017: 4 papers · 2018: 3 papers · 2019: 2 papers · 2020: 3 papers · 2021: 8 papers · 2022: 5 papers · 2023: 8 papers · 2024: 3 papers · 2025: 3 papers · 2026: 6 papers

Papers 50 of 52

  1. Carbon ion radiotherapy for non-metastatic pancreatic cancer: final results of the prospective phase 2 PACK-study (NCT04194268). Co-author DOI 10.1016/j.radonc.2026.111836↗
  2. The PREOPANC-2 trial in resectable and borderline resectable pancreatic cancer. First author DOI 10.1016/s1470-2045(25)00601-1↗
  3. New implications from long-term outcomes of perioperative therapy in resectable pancreatic cancer. Co-author DOI 10.1038/s41416-025-03295-9↗
  4. Daraxonrasib or Chemotherapy in Previously Treated Metastatic Pancreatic Cancer. Co-author DOI 10.1056/nejmoa2605555↗
  5. NQO1 as a predictor of response to adjuvant GemCap treatment for pancreatic cancer. Co-author DOI 10.1093/jnci/djaf345↗
  6. Neoadjuvant therapy for left-sided resectable pancreatic ductal adenocarcinoma: evidence-based shift or premature extrapolation? First author DOI 10.21037/hbsn-2025-587↗
  7. De novo induction of tertiary lymphoid structures: an immunotherapeutic strategy in pancreatic cancer. First author DOI 10.1038/s41392-025-02260-5↗
  8. Reply to: Adjuvant Treatment Options and Modalities in Pancreatic Adenocarcinoma: Insights From ESPAC4. Co-author DOI 10.1200/jco-25-00333↗
  9. Pancreatic Adenocarcinoma: Long-Term Outcomes of Adjuvant Therapy in the ESPAC4 Phase III Trial. Co-author DOI 10.1200/jco.24.01118↗
  10. Metavert synergises with standard cytotoxics in human PDAC organoids and is associated with transcriptomic signatures of therapeutic response. Co-author DOI 10.1016/j.tranon.2024.102109↗
  11. Tumour plasticity and tumour microenvironment interactions as potential immunologic targets for pancreatic cancer treatment. First author DOI 10.21037/cco-24-72↗
  12. ESMO 2023 pancreatic cancer guidelines signal stepwise progress. Co-author DOI 10.21037/hbsn-24-37↗
  13. Immediate surgery compared with short-course neoadjuvant gemcitabine plus capecitabine, FOLFIRINOX, or chemoradiotherapy in patients with borderline resectable… Co-author DOI 10.1016/s2468-1253(22)00348-x↗
  14. Neoadjuvant therapy for pancreatic cancer. Co-author DOI 10.1038/s41571-023-00746-1↗
  15. Persister cell phenotypes contribute to poor patient outcomes after neoadjuvant chemotherapy in PDAC. Co-author DOI 10.1038/s43018-023-00628-6↗
  16. Refining the Treatment of Pancreatic Cancer From Big Data to Improved Individual Survival. Co-author DOI 10.1093/function/zqad011↗
  17. Protocol of the IntenSify-Trial: An open-label phase I trial of the CYP3A inhibitor cobicistat and the cytostatics gemcitabine and nab-paclitaxel in patients w… Last author DOI 10.1111/cts.13661↗
  18. Interpreting Primary End Points in Randomized Trials of Pancreatic Cancer. Co-author DOI 10.1200/jco.23.00779↗
  19. Corrigendum: Clinical impact of molecular subtyping of pancreatic cancer. Co-author DOI 10.3389/fcell.2023.1179559↗
  20. Sex Differences in the Systemic and Local Immune Response of Pancreatic Cancer Patients. Co-author DOI 10.3390/cancers15061815↗
  21. CEND-1: a game changer for pancreatic cancer chemotherapy? Co-author DOI 10.1016/s2468-1253(22)00197-2↗
  22. The role of neoadjuvant therapy for resectable pancreatic cancer remains uncertain. Co-author DOI 10.1038/s41571-022-00612-6↗
  23. Tertiary lymphoid structures and their association to immune phenotypes and circulatory IL2 levels in pancreatic ductal adenocarcinoma. Co-author DOI 10.1080/2162402x.2022.2027148↗
  24. Actual Five-year Survival After Upfront Resection for Pancreatic Ductal Adenocarcinoma: Who Beats the Odds? Co-author DOI 10.1097/sla.0000000000004147↗
  25. Immune features of the peritumoral stroma in pancreatic ductal adenocarcinoma. Co-author DOI 10.3389/fimmu.2022.947407↗
  26. A Review of Pancreatic Cancer. First author DOI 10.1001/jama.2021.20065↗
  27. Poly(ADP-ribose) polymerase inhibition in pancreatic cancer. Last author DOI 10.1002/gcc.22932↗
  28. Quality of life and outcome of patients with metastatic pancreatic cancer receiving first-line chemotherapy with nab-paclitaxel and gemcitabine: Real-life resu… Co-author DOI 10.1002/ijc.33336↗
  29. Peripheral blood and tissue assessment highlights differential tumor-circulatory gradients of IL2 and MIF with prognostic significance in resectable pancreatic… Co-author DOI 10.1080/2162402x.2021.1962135↗
  30. Langerhans islets induce anti-tumor immunity at the expense of glycemic control and predict chemotherapy response in pancreatic cancer Co-author DOI 10.1101/2021.03.13.435100↗
  31. Phase 2 Trial of Oncolytic H-1 Parvovirus Therapy Shows Safety and Signs of Immune System Activation in Patients With Metastatic Pancreatic Ductal Adenocarcino… Co-author DOI 10.1158/1078-0432.ccr-21-1020↗
  32. Perioperative immunotherapy for pancreatic cancer is on its way. Co-author DOI 10.21037/hbsn-21-238↗
  33. Clinical Impact of Molecular Subtyping of Pancreatic Cancer. Co-author DOI 10.3389/fcell.2021.743908↗
  34. [Neoadjuvant and adjuvant treatment of pancreatic cancer]. Co-author DOI 10.1007/s00104-020-01169-9↗
  35. Induction chemotherapy in pancreatic cancer: CA 19-9 may predict resectability and survival. Co-author DOI 10.1016/j.hpb.2019.06.012↗
  36. Cetuximab in Pancreatic Cancer Therapy: A Systematic Review and Meta-Analysis. Co-author DOI 10.1159/000502844↗
  37. Chemotherapy for pancreatic cancer. Co-author DOI 10.1016/j.lpm.2019.02.025↗
  38. Protocol of a prospective, monocentric phase I/II feasibility study investigating the safety of multimodality treatment with a combination of intraoperative ch… First author DOI 10.1136/bmjopen-2018-028696↗
  39. A phase 1 trial extension to assess immunologic efficacy and safety of prime-boost vaccination with VXM01, an oral T cell vaccine against VEGFR2, in patients w… Co-author DOI 10.1080/2162402x.2017.1303584↗
  40. Pancreatic Ductal Adenocarcinoma Subtyping Using the Biomarkers Hepatocyte Nuclear Factor-1A and Cytokeratin-81 Correlates with Outcome and Treatment Response. Co-author DOI 10.1158/1078-0432.ccr-17-2180↗
  41. NRG1 Fusions in KRAS Wild-Type Pancreatic Cancer. Co-author DOI 10.1158/2159-8290.cd-18-0036↗
  42. High prevalence of incidental and symptomatic venous thromboembolic events in patients with advanced pancreatic cancer under palliative chemotherapy: A retrosp… Last author DOI 10.1016/j.pan.2017.04.012↗
  43. Pancreatic Cancer Surgery: The New R-status Counts. Co-author DOI 10.1097/sla.0000000000001731↗
  44. Palliative chemotherapy for pancreatic adenocarcinoma: a retrospective cohort analysis of efficacy and toxicity of the FOLFIRINOX regimen focusing on the older… Last author DOI 10.1186/s12876-017-0709-3↗
  45. A non-controlled, single arm, open label, phase II study of intravenous and intratumoral administration of ParvOryx in patients with metastatic, inoperable pan… Co-author DOI 10.1186/s12885-017-3604-y↗
  46. Locally Advanced Pancreatic Cancer: Neoadjuvant Therapy With Folfirinox Results in Resectability in 60% of the Patients. Co-author DOI 10.1097/sla.0000000000001850↗
  47. Anti-angiogenic activity of VXM01, an oral T-cell vaccine against VEGF receptor 2, in patients with advanced pancreatic cancer: A randomized, placebo-controlle… Co-author DOI 10.1080/2162402x.2014.1001217↗
  48. Patients with Advanced Pancreatic Cancer and Hyperbilirubinaemia: Review and German Expert Opinion on Treatment with nab-Paclitaxel plus Gemcitabine. Co-author DOI 10.1159/000441310↗
  49. Adjuvant radiotherapy and chemoradiation with gemcitabine after R1 resection in patients with pancreatic adenocarcinoma. Co-author DOI 10.1186/s12957-015-0560-3↗
  50. Chemotherapy for advanced pancreatic adenocarcinoma in elderly patients (≥70 years of age): a retrospective cohort study at the National Center for Tumor Disea… Last author DOI 10.1016/j.pan.2014.03.004↗

Closest collaborators

The 25 strongest of 147 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. John P. Neoptolemos · 23 shared papers, 2019–2026 · strength 5.06
  2. Thilo Hackert · 28 shared papers, 2013–2026 · strength 4.21
  3. Markus Wolfgang Büchler · 18 shared papers, 2013–2026 · strength 2.44
  4. Christoph W. Michalski · 10 shared papers, 2016–2026 · strength 2.08
  5. Peter J. Bailey · 10 shared papers, 2021–2025 · strength 1.78
  6. Niels Halama · 8 shared papers, 2017–2025 · strength 1.32
  7. Azaz Ahmed · 7 shared papers, 2021–2025 · strength 1.31
  8. Thomas P. Hank · 4 shared papers, 2017–2026 · strength 0.80
  9. Nathalia A. Giese · 6 shared papers, 2018–2023 · strength 0.80
  10. Rosa Klotz · 5 shared papers, 2021–2023 · strength 0.74
  11. Susanne Roth · 5 shared papers, 2019–2024 · strength 0.74
  12. Xu Zhou · 5 shared papers, 2021–2024 · strength 0.73
  13. Daniel H. Palmer · 4 shared papers, 2019–2025 · strength 0.70
  14. Daniel Öhlund · 2 shared papers, 2026 · strength 0.69
  15. Jingyu An · 4 shared papers, 2021–2024 · strength 0.54
  16. Oliver Strobel · 6 shared papers, 2016–2023 · strength 0.53
  17. Daniel H. Palmer · 2 shared papers, 2026 · strength 0.52
  18. Paula Ghaneh · 3 shared papers, 2023–2026 · strength 0.50
  19. Christopher Michael Halloran · 3 shared papers, 2023–2026 · strength 0.50
  20. Nicolas Hohmann · 5 shared papers, 2015–2023 · strength 0.46
  21. Martin Loos · 2 shared papers, 2024–2026 · strength 0.46
  22. Pascal R. Hammel · 2 shared papers, 2025–2026 · strength 0.39
  23. Markus K. Diener · 4 shared papers, 2015–2022 · strength 0.36
  24. Anne Katrin Berger · 4 shared papers, 2014–2021 · strength 0.34
  25. Jens Thomas Siveke · 3 shared papers, 2015–2023 · strength 0.33

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.